Key Points•Risk factors should weigh heavily on the decision to admit in patients with suspected community-acquired pneumonia (CAP), including advanced age, comorbid conditions, and physical examination, laboratory, and chest radiograph findings, all of which support the diagnosis (strength of recommendation: C).•First-line antibiotic therapy for acute bacterial rhinosinusitis should include amoxicillin or trimethoprim/sulfamethoxazole (TMP/SMX) for 7--10 days (strength of recommendation: A).•High-dose amoxicillin (80--90 mg/kg divided twice daily for 5--7 days) is the antibiotic of choice for the initial treatment of acute otitis media (AOM) (strength of recommendation: B); lack of subjective improvement after 72 hours of treatment with amoxicillin indicates treatment failure, at which point the patient should be switched to amoxicillin/clavulanate. Patients with persistent symptoms after therapy with high-dose amoxicillin/clavulanate should receive 1--3 doses of intramuscular ceftriaxone (strength of recommendation: B).•Pharmacotherapy treatment for influenza should be initiated within 48 hours of the start of symptoms, and it has been shown to reduce the duration of symptoms by only 1 day compared with placebo (strength of recommendation: B).•The American Association for the Study of Liver Diseases recommends that persons at high risk of infection, recipients of transfusions or organ transplants before July 1992 (when HCV screening became standard), healthcare workers after a needlestick injury, and sexual partners of HCV-infected persons be tested for HCV infection (strength of recommendation: C).•Currently, not all patients with HIV infection require the use of antiretroviral medication. Because of the adverse effects and the risk of the development of resistance associated with treatment, these medications are now initiated only when the CD4 count falls to below 350 cells/mL or in the setting of acute infection (strength of recommendation: B).•More severe immune compromise occurs in HIV-positive patients at CD4 count levels of less than 200 cells/mL, at which point prophylactic antibiotics such as TMP/SMX are recommended (strength of recommendation: B).•In cases of traveler\'s diarrhea (e.g., enterotoxigenic *E. coli, Shigella, Salmonella, or Campylobacter* infection), prompt treatment with a fluoroquinolone or, in children, TMP/SMX has been shown to reduce the duration of the illness from 3--5 days to less than 1--2 days (strength of recommendation: A).•Patients with fever and bloody diarrhea should be treated empirically with TMP/SMZ or a fluoroquinolone (strength of recommendation: A).•Recommended treatment regimens for gonococcal urethritis and proctitis include ceftriaxone, cefixime, ciprofloxacin, ofloxacin, or levofloxacin in single doses; if chlamydial infection is not ruled out and suspicion is high, then azithromycin or doxycycline should be given concomitantly (strength of recommendation: A).•Parenteral administration of penicillin G is the preferred drug for treatment for all stages of syphilis (strength of recommendation: A).

Introduction {#s0010}
============

Infectious diseases are a leading cause of morbidity and mortality in men in all parts of the world. Given the broad scope of infectious diseases that affect men, we have selected several topics that are especially relevant to this patient population. These topics include community-acquired pneumonia (CAP), sinusitis, otitis media and externa, influenza, viral hepatitis (A, B and C), human immunodeficiency virus (HIV) infection, infectious diarrheas, and sexually transmitted diseases. Our aim in this chapter is not to provide an exhaustive review of these topics, but primarily to present an up-to-date and evidence-based approach to diagnosis and treatment of these common illnesses for primary care physicians in caring for male patients.

Community-Acquired Pneumonia {#s0020}
============================

Epidemiology/Pathogenesis {#s0030}
-------------------------

CAP is a serious illness that affects up to 4.5 million people in the United States annually, resulting in hospitalization in approximately 20% of these cases.[@bib0010] With a mortality rate of 5.1%, this disease is the sixth most common cause of death in the United States.[@bib0020] Empiric antibiotic therapy is necessary since an etiologic organism is not identified in well over 50% of cases. Further complicating the treatment of CAP is the emergence of antibiotic resistant *Streptococcus pneumoniae,* perhaps the most common organism implicated.[@bib0010] The rates of pneumonia are higher in men discharged from the hospital (4.1% in men versus 3.1% in women).[@bib0020]

Microaspiration of organisms is the most common mechanism of infection leading to CAP, though hematogenous spread can also occur.[@bib0030] Host factors that predispose patients to an increased risk of the development of CAP include smoking, underlying lung disease (e.g., chronic obstructive pulmonary disease \[COPD\], bronchiectasis), uremia, malnutrition, alcohol abuse, ciliary motility defects (e.g., Kartagener\'s syndrome), alterations in consciousness, immunosuppression (e.g., HIV/acquired immunodeficiency syndrome \[AIDS\], corticosteroid use), advanced age, and gastric acid suppression.[@bib0040] Both bacterial and viral virulence factors play a significant role in the development of CAP.

More than 100 microorganisms have been implicated as causative agents in CAP.[@bib0010] The most common "typical" bacterial etiologies include *S. pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis,* group A *Streptococcus*, and various anaerobic and gram-negative bacteria. The most common "atypical" bacteria include *Legionella* species, *Mycoplasma pneumoniae,* and *Chlamydia pneumoniae.* Although influenza is the most common cause of viral CAP, adenovirus and parainfluenza virus pneumonias also occur, and respiratory syncytial virus is a significant pathogen in infants. A newly emerged strain of corona virus led to an epidemic outbreak of severe acute respiratory syndrome in China and Canada in 2003. [Table 11-1](#t0010){ref-type="table"} highlights the most common causes of CAP in three settings: ambulatory care, hospital non--intensive care unit (ICU), and the ICU.Table 11-1Major Etiologies of Community-Acquired Pneumonia with Regard to SettingOrganismAmbulatoryHospitalizedICU*Mycoplasma pneumoniae*16%6%\< 1%Respiratory viruses15%10%4%*Streptococcus pneumoniae*14%25%17%*Chlamydia pneumoniae*12%3%\<1%*Legionella* species2%3%10%*Haemophilus influenzae*1%5%3%Gram-negative rods\< 1%\<1%5%Unknown44%37%41%Adapted from: Niederman MS, Mandell LA, Anzueto A, et al: Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention, *Am J Respir Crit Care Med* 163:1730--1754, 2001.

Diagnosis {#s0040}
---------

Pneumonia should be suspected in any patient who presents with cough, productive sputum, and dyspnea, especially if a fever is present. Elderly patients with pneumonia may not have fever or respiratory symptoms and frequently present with failure to thrive or confusion.[@bib0020] In these patients, tachypnea and abnormal pulmonary examination results exhibited by rhonchi, abnormal breath sounds, tactile fremitus, and egophony will often aid in the diagnosis.

The American Thoracic Society Guidelines[@bib0050] state that the initial diagnostic evaluation of a patient with suspected CAP should include a chest radiograph and a sputum Gram stain and culture. A chest radiograph can be used to determine the extent (unilobar versus multilobar) and character (interstitial infiltrate versus consolidation) of the pneumonia, and sputum studies will guide specific therapy.[@bib0010] There is some controversy regarding the use of Gram stain and culture because of poor sensitivity and specificity, but some groups still consider these tests useful in targeting initial therapy.[@bib0040] These guidelines recommend the use of sputum Gram stain and culture if the presence of drug-resistant bacteria or an organism not covered by empiric therapy is suspected.[@bib0010]

Pulse oximetry, a complete blood count with platelets and differential, serum electrolyte and hepatic enzyme measurements, and renal function tests may be helpful prognostic tools to help identify patients requiring hospitalization. Admitted patients with severe illness or with chronic lung disease should have an arterial blood gas performed to assess for oxygenation and hypercapnia.[@bib0010] Hospitalized patients should have two sets of blood cultures drawn, and patients with pleural effusions should undergo thoracentesis to assess for empyema or complicated parapneumonic effusions.[@bib0040] Serologic antibody testing and cold agglutinin assays are not helpful initially and should only be performed if the patient\'s condition does not improve or for epidemiologic purposes.[@bib0040]

Treatment {#s0050}
---------

Although clinical prediction rules are useful when deciding whether a patient with CAP should be admitted to the hospital for observation and treatment, these rules should not supplant clinical judgment.[@bib0020] Generally, the following risk factors should weigh heavily on the decision to admit:[@bib0050] •Age older than 65 years•Coexisting illness: COPD, diabetes mellitus, renal insufficiency, congestive heart failure, chronic liver disease, alcohol abuse, post-splenectomy status•Physical findings: respiratory rate \> 30 breaths/min, systolic blood pressure \< 90 mm Hg, diastolic blood pressure \< 60 mm Hg, pulse rate \> 125 beats/min, temperature \> 40°C, confusion, or decreased consciousness•Laboratory findings: white blood count \< 4 × 10^9^ cells/liter or \> 30 × 10^9^ cells/liter, hematocrit \< 30%, PaO~2~ \< 60 mm Hg, PaCO~2~ \> 50 mm Hg, pH \< 7.35, creatinine \> 1.2 mg/dL, or BUN \> 20 mg/dL•Chest x-ray: cavitation, multilobar pneumonia, pleural effusion

Empiric antibiotics are generally recommended as initial therapy for CAP ([Table 11-2](#t0020){ref-type="table"} ).[@bib0060] Table 11-2Treatment of Community-Acquired Pneumonia with Regard to Setting**Outpatient**No recent antibioticsErythromycin 1--4 g/day for 7--10 days or clarithromycin 1 g/day for 7--10 days or azithromycin 500 mg on first day then 250 mg for 4 daysDoxycycline 100 mg bid for 7--10 daysRecent antibiotics (within 3 months) or comorbidities (e.g., COPD, diabetes, liver or renal disease, heart failure)Levofloxacin (Levaquin) 750 mg/day or gatifloxacin (Tequin) 400 mg/day or moxifloxacin (Avelox) 400 mg/day or gemifloxacin (Factive) 320 mg/day for 7--10 daysTelithromycin (Ketek) 800 mg/day for 7--10 daysAmoxicillin (Amoxil; Trimox) 3--4 g/day or Amoxicillin/clavulanate (Augmentin) 4 g/day + advanced macrolide (clarithromycin, azithromycin) or doxycycline (see above) for 7--10 daysCefpodoxime (Vantin) 200 mg bid or cefuroxime (Ceftin) 200 mg bid + advanced macrolide (clarithromycin, azithromycin) or doxycycline (see above) for 7--10 days**Hospitalized, non-ICU**Ceftriaxone (Rocephin) 2 g/day IV or cefotaxime (Claforan) 1 g IV every 8 hours + azithromycin 500 mg/day IV until clinically improved then oral antibiotics (see above) for a total of 7--10 daysLevofloxacin (Levaquin) 750 mg/day or gatifloxacin (Tequin) 400 mg/day or moxifloxacin (Avelox) 400 mg/day or gemifloxacin (Factive) 320 mg/day for 7--10 daysAmpicillin/sulbactam (Unasyn) 1.5--3 g every 6 hours IV until clinically improved then oral antibiotics (see above) for a total of 7--10 daysErtapenem (Invanz) 1 g/day until clinically improved then oral antibiotics (see above) for a total of 7--10 days**ICU**No penicillin allergyCeftriaxone (Rocephin) 2 g/day IV or cefotaxime (Claforan) 1 g IV every 8 hours + azithromycin 500 mg/day IV or fluoroquinolone PO or IV (see above for dosing) until clinically improved then oral antibiotics (see above) for a total of 7--10 daysIf patient is severely ill or staphylococcal infection is suspected, add vancomycin 1 g every 12 hours IV or linezolid (Zyvox) 600 mg every 12 hours IV until culture results and susceptibility testing are knownPenicillin-allergicLevofloxacin (Levaquin) 750 mg/day or gatifloxacin (Tequin) 400 mg/day or moxifloxacin (Avelox) 400 mg/day or gemifloxacin (Factive) 320 mg/day ± clindamycin (Cleocin) 600--1200 mg/day IV for 7--10 daysIf patient is severely ill or staphylococcal infection is suspected, add vancomycin 1 g every 12 hours IV or linezolid (Zyvox) 600 mg every 12 hours IV until culture results and susceptibility testing are known**Drug-Resistant *Streptococcus pneumoniae***Reduced susceptibility to penicillin (MIC ≥ 2 μg/mL) but MICs to cefotaxime or ceftriaxone of ≤ 2 μg/mL without meningitisCeftriaxone or cefotaxime (see above)Alternative: fluoroquinolones (see above) although not effective in meningitisMIC ≥ 4 μg/mL to cefotaxime and ceftriaxoneFluoroquinolones (see above) although not effective in meningitisAlternative: vancomycin, linezolid, telithromycin (outpatients), (see above)[^1]Adapted from: Mandell LA, Bartlett JG, Dowell SF, et al: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults, *Clin Infect Dis* 37(11):1405--1433, 2003.

Complications {#s0060}
-------------

A patient with CAP should respond to adequate antibiotic therapy within 4 days of initiation of treatment with decreased fever, improved clinical status (e.g., decreased dyspnea and normalized blood pressure), and a decrease in the white blood cell count.[@bib0010] If the patient\'s condition fails to improve or worsens during therapy, then a workup for complications of pneumonia should be initiated. Pulmonary complications of pneumonia include lung abscess, parapneumonic effusion, and empyema.[@bib0010] Although findings on a chest radiograph can remain abnormal for 4 weeks or longer after diagnosis of CAP, repeat imaging via either computerized tomography scan of the chest or follow-up chest radiograph may be helpful in patients whose conditions fail to improve or worsen over time.[@bib0010] Other complications, particularly resulting from *S. pneumoniae* bacteremia, include meningitis, endocarditis, and pericarditis. Acute respiratory distress syndrome may also occur with severe illness and may necessitate intubation.[@bib0010]

Vaccination {#s0070}
-----------

The 23-valent purified capsular polysaccharide pneumococcal vaccine offers protection against 85--90% of invasive strains of bacteria that can cause CAP.[@bib0010] Patients with risk factors that place them at a greatly elevated risk of development of CAP should be strongly encouraged to receive the pneumococcal vaccine ([Table 11-3](#t0030){ref-type="table"} ). A single vaccine can be given to patients aged 65 years or older, including those who received vaccine more than 5 years before turning 65 years old. Repeat vaccination is indicated after 5 years in immunocompromised patients. A yearly influenza vaccine should be administered concomitantly to patients with any of the above risk factors.[@bib0010] Table 11-3Risk Factors for the Development of Community-Acquired Pneumonia• Age 65 years or older• Alcoholism• Asplenia• Cerebrospinal fluid leaks• Chronic obstructive pulmonary disease• Chronic renal disease• Diabetes mellitus• Immunosuppressed patients, including patients taking corticosteroids and those with hematologic malignancies• Liver diseaseAdapted from: Niederman MS, Mandell LA, Anzueto A, et al: Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention, *Am J Respir Crit Care Med* 163:1730--1754, 2001.

Acute Sinusitis {#s0080}
===============

Epidemiology/Pathogenesis {#s0090}
-------------------------

There are approximately 20 million cases of acute bacterial sinusitis annually in the United States,[@bib0070] most of which result from the common colds and influenza-like illnesses occurring an average of two to three times per year in adults. It is estimated that 0.5--2% of all acute respiratory illnesses result in sinusitis. Viral, bacterial, and fungal causes of acute sinusitis have all been implicated ([Table 11-4](#t0040){ref-type="table"} ). The healthcare costs related to the diagnosis and management of sinusitis are estimated to be close to \$4 billion annually.Table 11-4Microbiology and Incidence of Acute SinusitisPercentage (%)**Viruses**Rhinovirus15Influenza virus5Parainfluenza virus3Adenovirus---**Bacteria***Streptococcus pneumoniae*31*Haemophilus influenzae*21Alpha-streptococci9Gram-negative bacteria9*Moraxella catarrhalis*8Anaerobes6*S. pneumoniae + H. influenzae*5*Staphylococcus aureus*4*Streptococcus pyogenes*2Adapted from: Gwaltney JM: Sinusitis. In Mandell GL, Bennett JE, Dolan R, editors: *Mandell, Douglas, and Bennett\'s Principles and Practice of Infectious Diseases*, ed 5, Philadelphia, 2000, Churchill Livingstone, pp 676--686.

The most common predisposing condition associated with bacterial sinusitis is a viral infection that results in thickening of the sinus mucosa and subsequent obstruction of the ostia.[@bib0070] The resultant accumulation of secretions allows for bacterial colonization of the normally sterile sinus mucosa. The maxillary sinus is the most commonly involved (87%), followed by the ethmoidal (65%), sphenoid (39%), and frontal (32%) sinuses.[@bib0080] Other risk factors include swimming (e.g., microaspiration of contaminated water), allergies, nasal obstruction (e.g., polyps, tumors), decreased mucociliary activity (e.g., cystic fibrosis, smoking), granulomatous disease (e.g., Wegener\'s granulomatosis), and immunosuppression (e.g., HIV/AIDS, chronic corticosteroid use). Dental infections of the upper teeth, particularly the second bicuspids and first and second molars, are responsible for 5--10% of cases of maxillary sinusitis. Environmental factors including high altitude, air pollution, and living in the Midwest or southern United States increase the risk of acute bacterial sinusitis. Females seem to be at higher risk than males; overall, elderly persons are at an increased risk of development of sinusitis.[@bib0080]

Clinical Presentation {#s0100}
---------------------

Symptoms of acute sinusitis, particularly maxillary sinusitis, include congestion, purulent nasal discharge, facial pain, and maxillary tooth discomfort for less than 4 weeks.[@bib0090] It is often reported that facial pain is exacerbated by bending forward. Less specific symptoms including headache, fever, fatigue, and halitosis may also occur. A high fever, acute facial pain, periorbital edema, diplopia, or a change in mental status warrant an immediate evaluation for potential neurologic complications of acute sinusitis.

Diagnosis {#s0110}
---------

The diagnosis of acute bacterial sinusitis is imprecise and, although most cases are likely to be viral rhinosinusitis, primary care physicians prescribe an antibiotic in 85--98% of cases.[@bib0100] The Centers for Disease Control and Prevention endorse antibiotic treatment of acute sinusitis in patients who have persistent nasal discharge for longer than 7 days, maxillary sinus pain, and facial or tooth tenderness.[@bib0100] Sinus radiography is not recommended in uncomplicated acute sinusitis because it is thought to be inaccurate.[@bib0100] Sinus transillumination has limited value as a diagnostic tool because it does not distinguish bacterial from viral sinusitis. Sinus aspiration should not be used for routine evaluation of uncomplicated acute sinusitis because it is both invasive and expensive. Computerized tomography scanning of the sinuses should be limited to refractory or chronic cases of sinusitis because this modality does not accurately distinguish between bacterial and viral causes.[@bib0100]

Treatment {#s0120}
---------

Symptoms of acute sinusitis resolve within 2 weeks without antibiotic therapy in 70% of cases and with antibiotics in 85% of cases.[@bib0110] Recent guidelines by the Sinus and Allergy Health Partnership recommend treatment for acute bacterial sinusitis in patients who have symptoms of sinusitis and have not improved in 10 days or in those whose conditions worsen after 5--7 days.[@bib0120] First-line antibiotic therapy for acute bacterial rhinosinusitis should include amoxicillin or trimethoprim/sulfamethoxazole (TMP/SMX) for 7--10 days. These agents have been proved to be superior to placebo and are as effective as other agents that are more expensive, have a greater risk of adverse effects, and should be reserved for more serious infections that require treatment with amoxicillin-clavulanate, cefuroxime, or cefpodoxime.[@bib0110] For partial but incomplete resolution of symptoms after an initial course of antibiotics, the duration of initial therapy should be extended to complete a course for 21 days. In patients with moderate disease or in those with minimal to no improvement with initial therapy, high-dose amoxicillin-clavulanate or levofloxacin should be used.[@bib0110] In areas of the United States where there is a high level of penicillin-resistant *S. pneumoniae,* resistance to macrolides and TMP/SMX will also be prevalent, and second-generation cephalosporins (e.g., cefuroxime) should be used as initial therapy.[@bib0070] More recently, high-dose short-course regimens (3--5 days) have been used to improve adherence and to decrease drug exposure.[@bib0070] Clinical outcomes using these regimens compare favorably to more traditional 10--14-day regimens.[@bib0130] [Table 11-5](#t0050){ref-type="table"} highlights examples of both long- and short-course treatments.Table 11-5Empiric Therapy of Acute Bacterial Sinusitis**Mild Disease**Amoxicillin/clavulanate (Augmentin) 1.75--4 g/day for 10 daysAmoxicillin[\*](#tn0010){ref-type="table-fn"} (Amoxil; Trimox) 1.5--4 g/day for 10 daysCefpodoxime (Vantin) 200 mg every 12 hours for 10 daysCefuroxime (Ceftin) 200 mg every 12 hours for 10 daysCefdinir (Omnicef) 600 mg/day for 10 days**Mild Disease in Patients with Beta Lactam Allergy**Trimethoprim/sulfamethoxazole[\*](#tn0010){ref-type="table-fn"} (Bactrim) DS every 12 hours for 10 daysDoxycycline (Vibramycin) 100 mg every 12 hours for 10 daysAzithromycin (Zithromax) 500 mg/day for 5 days; clarithromycin (Biaxin) 500 mg every 12 hours for 14 days; erythromycin 250 mg qid for 10 daysTelithromycin (Ketek) 800 mg/day for 10 days**Mild to Moderate Disease in Patients with Recent Antibiotic Therapy**Gatifloxacin (Tequin) 400 mg/day; levofloxacin (Levaquin) 500 mg/day; moxifloxacin (Avelox) 400 mg/day for 10--14 daysAmoxicillin/clavulanate (Augmentin) 4 g/day for 10 daysCeftriaxone (Rocephin) 1--2 g IV/IM once a day for 10 daysAmoxicillin 4 g/day + rifampin (Rifadin) 600 mg/day for 10 daysClindamycin (Cleocin) 150--300 mg qid + rifampin 600 mg/day for 10 days**Short-course Regimens**Telithromycin (Ketek) 800 mg/day for 5 daysAzithromycin 500 mg/day for 3 daysGatifloxacin (Tequin) 400 mg/day for 5 days[^2][^3]Adapted from: Anon JB, Jacobs MP, Poole MD: Antimicrobial treatment guidelines for acute bacterial rhinosinusitis: executive summary of the Sinus and Allergy Health Partnership (SAHP), *Otolarygol Head and Neck Surg* 130:1--45, 2004; and Sher LD, McDoo MA, Bettis RB, Turner MA, Li NF, Pierce PF: A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10 day amoxicillin/clavulanate in patients with acute bacterial sinusitis, *Clin Ther* 24:269--281, 2002.

Complications {#s0130}
-------------

Complications of acute sinusitis include orbital cellulitis (most common), Pott puffy tumor (a cellulitis over the frontal sinus), intracranial abscesses, meningitis, and cavernous sinus thrombosis.[@bib0070] These complications often require surgical drainage and intravenous antibiotics. Nasal culture specimens should be obtained to guide therapy in complicated or refractory cases, but initial treatment with broad-spectrum antibiotics, including ceftriaxone with or without an aminoglycoside given intravenously, is often warranted until cultures are proved to be positive.[@bib0140] Acute sinusitis is a precursor to chronic sinusitis; in addition to aerobic bacteria, fungi and anaerobic bacteria play a significant role in chronic sinusitis.

Acute Otitis Media/Otitis Externa {#s0140}
=================================

Acute Otitis Media {#s0150}
------------------

Acute otitis media (AOM) is predominantly a disease of infants and children with the highest incidence occurring between the ages of 6 and 24 months and is less commonly seen in adults. The cost of treating AOM in the United States was estimated at \$3.8 billion in 1995 (the most recent accurate estimate).[@bib0150] In childhood, boys are affected more frequently than girls. AOM is characterized by a middle ear effusion demonstrated via pneumatic otoscopy, tympanometry, an air fluid level, or a bulging tympanic membrane; evidence of acute inflammation with an opaque, white, yellow, or erythematous tympanic membrane or purulent effusion; and symptoms of otalgia, irritability, or fever.[@bib0160] Otitis media with effusion presents in a similar fashion, and a purulent collection of fluid behind the tympanic membrane can be visualized. Unless drainage from the external auditory canal exists, microbiologic diagnosis is usually not feasible and only rarely necessary. The most common organisms that cause AOM include *S. pneumoniae, H. influenzae,* and *M. catarrhalis*.

Patients who have no improvement in subjective symptoms, especially fever, after 48--72 hours of observation should be considered for antibiotic treatment. Although it is universally held that many physicians still overtreat AOM with antibiotics, expert opinion states that antibiotic therapy can be deferred for many asymptomatic patients and for most cases of otitis media with effusion.[@bib0160] Children younger than 2 years of age and those with recurrent bouts of AOM are more likely to be appropriately treated with antibiotic therapy.[@bib0170] High-dose amoxicillin, 80--90 mg/kg divided twice daily for 5--7 days, is the antibiotic of choice for the initial treatment of AOM.[@bib0160] Lack of subjective improvement after 72 hours of treatment with amoxicillin suggests treatment failure, and the patient should be switched to amoxicillin/clavulanate; patients with persistent symptoms after administration of high-dose amoxicillin/clavulanate should receive 1--3 doses of intramuscular ceftriaxone.[@bib0160] In cases of suspected resistant organisms, macrolides (e.g., azithromycin), TMP/SMX, cephalexin, cefaclor, loracarbef, and cefdinir can also be used. Multiple courses of broad-spectrum antibiotics should be avoided; routine prophylactic therapy is not recommended for recurrent AOM.[@bib0160] Complications of AOM include hearing loss, chronic otitis media, tympanic membrane perforation, and mastoiditis. Rare complications include brain/epidural/subdural abscesses, meningitis, and lateral sinus or cavernous vein thrombosis.

Otitis Externa {#s0160}
--------------

Otitis externa (OE) is an infection of the external auditory canal that primarily affects children but is not uncommon among adults, particularly in persons with diabetes and immunocompromised patients.[@bib0180] Up to 10% of the population will develop OE at some point during their lifetime; risk factors include excessive cleaning of the ear canal via cotton swabs or aggressive itching of the ear canal, swimming ("swimmer\'s ear"), increased humidity, and wearing ear canal devices such as hearing aids, headphones, or diving caps. Skin conditions including psoriasis, eczema, seborrheic dermatitis, and acne can increase the risk of OE if the ear is involved.[@bib0180]

Patients with OE typically present with otalgia and otorrhea.[@bib0180] Pain is commonly exacerbated by pulling on the ear lobe or sometimes, while chewing. If the auditory canal is occluded by fluid discharge, then the patient may complain of fullness and hearing loss. Fever and other systemic signs are uncommon in uncomplicated cases of OE. On physical examination, a serous or purulent exudate is commonly seen in the auditory canal, and pulling on the pinna elicits pain. Mastoid tenderness or crepitus suggests a more complicated infection; in these cases, mastoiditis should be strongly considered and a referral to an otolaryngologist promptly facilitated. An erythematous tympanic membrane indicates a concomitant otitis media.

The most common organisms causing OE include *Pseudomonas aeruginosa* (41%) and *S. aureus* (15%). Fungal organisms (*Aspergillus* species) are recovered in 6.5% of cases and one third of cases are polymicrobial, including anaerobes such as *Bacteroides fragilis* and *Peptostreptococcus* species.[@bib0190]

Cleansing the involved auditory canal with room temperature tap water should be attempted to optimize topical therapy and should be performed with low suction under direct visualization. Alternatively, a cotton swab can be used to gently mop secretions from the canal. Flushing of the external auditory canal should not be attempted unless an intact tympanic membrane is visualized. If the tympanic membrane has perforated, flushing may cause significant cochlear damage.

Therapies for the treatment of OE are listed in [Table 11-6](#t0060){ref-type="table"} ; topical antibiotics are the treatment of choice for uncomplicated OE. It is recommended that drops be given for 3 days after symptoms resolve, and most patients require a total of 5--7 days of treatment. The addition of steroids to ear drop solutions may help to decrease canal inflammation more quickly. If canal edema is severe, a wick placed in the canal may be required, and drops should be applied more frequently (6--10 times daily) until the canal is opened. Systemic antibiotics are rarely needed but are useful when OE is persistent or when concomitant OM is present.Table 11-6Treatment of Otitis ExternaTopical treatment2% acetic acid otic solution (VoSoL)• with hydrocortisone (VolSoL HC Otic)• with aluminum acetate (Otic Domeboro)Neomycin otic solution• with polymyxin B-hydrocortisone (Cortisporin)• with hydrocortisone-thonzonium (Coly-Mycin S)Polymyxin B-hydrocortisone (Otobiotic)Ophthalmic solutions• Ofloxacin 0.3% (Ocuflox)• Ciprofloxacin 0.3% (Ciloxan)• Gentamicin sulfate 0.3% (Garamycin)• Tobramycin sulfate 0.3% (Tobrex)Systemic antibiotics (IV or PO)• Cephalosporins: ceftazidime, cefepime• If OM present• Anti-pseudomonal penicillins: piperacillin, ticarcillin• Immunocompromised• Fluoroquinolones: ciprofloxacin, levofloxacin• Persistent OE• Best oral option (covers pseudomonas species)• Disease beyond auditory canal• Necrotizing OE should be treated with IV therapy and an otolaryngology consult should be called early for possible debridement• Necrotizing OE[^4]Adapted from: Sanders R: Otitis externa: a practical guide to treatment and prevention, *Am Fam Pract* 63:927--936, 2001.

Complications of OE include necrotizing OE, focal furuncles, mastoiditis, and chronic OE, which can lead to hearing loss.[@bib0180] Necrotizing OE is the life-threatening extension of OE into the mastoid and temporal bones. The most common etiologic agent is *P. aeruginosa,* and treatment often requires parenteral antibiotics and, periodically, surgery. An otolaryngologist should be consulted early when necrotizing OE is suspected. Those at highest risk include elderly persons, particularly those with diabetes and immunocompromised patients (e.g., HIV/AIDS).

Influenza {#s0170}
=========

Most human epidemics of influenza are caused by the type A and B influenza viruses.[@bib0200] Influenza A viruses, which also cause pandemics, are named by their hemagglutinin (H) and neuraminidase (N) surface antigens. Influenza B viruses are not categorized into subtypes and do not cause pandemics. Since 1977, influenza A H1N1, influenza A H3N2, and influenza B viruses have been circulating worldwide. In the last century there have been three pandemics of influenza A that occurred in 1918, 1957, and 1968. The most devastating of these pandemics was the 1918 outbreak of "Spanish flu," which killed 40--50 million people worldwide and 500,000 in the United States. The outbreak of avian influenza (H5N1) in Southeast Asia that started in 2003 and caused 70 deaths as of January 2006 has raised concern about a seemingly overdue pandemic.[@bib0210]

Epidemiology {#s0180}
------------

On average, approximately 36,000 people die from influenza-related complications and 226,000 are admitted to the hospital for influenza each year in the United States.[@bib0200] Very young children (0--4 years) and elderly persons (older than 65 years) compose the majority of these cases. The mortality rate in the 1990s for persons older than 65 years was 98.3/100,000 and was 7.5/100,000 in those aged 50--64 years. Influenza complications are also much more common in men with high-risk conditions including COPD, coronary heart disease, diabetes mellitus, immunodeficiency (e.g., HIV/AIDS), chronic corticosteroid use (e.g., \> 7.5 mg/day), hematologic cancers (e.g., leukemia), and chronic renal failure. Males may be disproportionately affected by influenza risk and contracture because they have a higher rate of many of these high-risk conditions.

Clinical Presentation {#s0190}
---------------------

Influenza is spread via person-to-person contact and, during an epidemic, 25--40% of unvaccinated susceptible persons will get infected and develop symptoms.[@bib0200] The incubation period is 1--4 days with an average of 2 days. Viral shedding occurs 1--2 days before the start of symptoms and continues for an average of 5--7 days thereafter; immunocompromised patients can shed the influenza virus for a period of weeks.

Uncomplicated influenza presents as an abrupt onset of fever, chills, headache, myalgias, nonproductive cough, sore throat, and rhinitis.[@bib0220] During influenza season, particularly if an epidemic is occurring, the specificity of clinical symptoms can be as high as 71%. Influenza usually resolves within 3--7 days, but cough and malaise may persist for several weeks. Complications of influenza in adults and adolescents include primary viral pneumonia, secondary bacterial pneumonias (e.g., *S. aureus*), bacterial sepsis, myositis, myocarditis and pericarditis, encephalitis, and transverse myelitis. Most deaths are a result of either viral or bacterial pneumonia.[@bib0220]

Diagnosis {#s0200}
---------

During influenza season, the diagnosis of the disease is made on the basis of clinical suspicion. The sensitivity and specificity of an influenza-like illness with fevers, myalgias, malaise, nonproductive cough, rhinitis, and headache are approximately 70% and 60%, respectively.[@bib0200] Available diagnostic tests for influenza include viral cultures, viral serologic assays, rapid antigen testing, and polymerase chain reaction (PCR) and immunofluorescence assays. Rapid influenza tests require nasopharyngeal swabs and are more than 70% sensitive and 90% specific. They are most useful at the start of the influenza season to confirm an epidemic (positive predictive value, 89--95%) and during non-influenza seasons when influenza is suspected (negative predictive value, 99%).[@bib0230] These tests can differentiate between influenza A and B but cannot identify specific influenza A subtypes (e.g., H3N2 versus H1N1). Other diagnostic tests have no clinical value at this time.

Vaccination {#s0210}
-----------

The best way to prevent influenza and its complications is through vaccination. Vaccination of healthy adults older than 65 years of age prevents influenza in 70--90% of vaccinated persons and significantly decreases work absenteeism and use of healthcare resources.[@bib0200] Among persons older than 65 years, vaccination is 50--60% effective in preventing influenza-related hospitalizations and 80% effective in preventing influenza-related death. A cost-benefit analysis estimated an average annual savings of \$13.66/person vaccinated.[@bib0240] Unfortunately, vaccination rates vary from 30% to 66% depending on the risk category, and healthcare worker vaccination rates are generally below 40%. Many people refuse influenza vaccination claiming that it has "given them the flu" or they "know someone who has gotten the flu from the vaccine." These perceptions persist regardless of much evidence to the contrary. Healthcare workers are often "too busy" to get vaccinated despite ample opportunity and education.

Two influenza vaccines are currently endorsed by the US Food and Drug Administration (FDA). The inactivated (killed virus) influenza vaccine is most commonly used and is given as an intramuscular injection. The live, attenuated influenza vaccine is administered intranasally as a spray. Both vaccines are equally effective for protection against influenza A and B, both are grown in egg albumin, and both are administered yearly. The live vaccine is more expensive than the inactivated vaccine and is not approved for use in children younger than 5 years old. Since it is a live virus, it should not be administered to immunosuppressed patients. Site reactions and fever have occurred with the inactivated vaccine, whereas very few adverse affects have been associated with the live formulation. The current Advisory Committee on Immunization Practices recommendations for vaccinating against influenza are summarized in [Table 11-7](#t0070){ref-type="table"} .Table 11-7ACIP Influenza Vaccination Recommendations (July 2005)High risk for influenza complications• Persons aged ≥65 years• Residents of nursing homes and other chronic-care facilities that house persons of any age who have chronic medical conditions• Adults and children who have chronic disorders of the pulmonary or cardiovascular systems, including asthma (hypertension is not considered a high-risk condition)• Adults and children who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus \[HIV\])• Adults and children who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration• Children and adolescents (aged 6 months to 18 years) who are receiving long-term aspirin therapy and, therefore, might be at risk for experiencing Reye\'s syndrome after influenza infection• Children aged 6--23 monthsPersons aged 50--64 yearsHealthcare workersPersons who can transmit influenza to those at riskTravelers (e.g., on cruise ships)General population---if vaccine supplies are adequateThe following groups should not be vaccinated with live, attenuated influenza vaccine (LAIV)• Persons aged \< 5 years or those aged ≥50 years• Persons with asthma, reactive airways disease, or other chronic disorders of the pulmonary or cardiovascular systems; persons with other underlying medical conditions, including such metabolic diseases as diabetes, renal dysfunction, and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases or who are receiving immunosuppressive therapies• Children or adolescents receiving aspirin or other salicylates (because of the association of Reye\'s syndrome with wild-type influenza infection)• Persons with a history of GBS• Persons with a history of hypersensitivity, including anaphylaxis, to any of the components of LAIV or to eggs[^5]Adapted from: Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices, *MMWR* 54:1--40, 2005.

Treatment {#s0220}
---------

Antiviral medications can be used as either treatment or chemoprophylaxis of influenza A and B[@bib0200] ([Table 11-8](#t0080){ref-type="table"} ), and there are currently four licensed drugs in two classes. Amantadine and rimantadine are only active against influenza A and are FDA approved for both treatment and prophylaxis in adults. Adverse effects include central nervous system (CNS) toxicity (e.g., anxiety, dizziness, insomnia, difficulty concentrating) and gastrointestinal toxicity (e.g., nausea, vomiting). These symptoms are usually mild and resolve with drug discontinuation. Severe adverse effects including delirium, seizures, and hallucinations are rare and only seen with high serum levels of the medications.Table 11-8Recommendations for Treatment and Prophylaxis of InfluenzaTreatment IndicationsMedication• Symptoms (e.g., fever, nonproductive cough, malaise, myalgias) for \<48 hours• Amantadine (Symmetrel) 100 mg bid PO × 3--5 days (reduce dose in elderly, in those with renal hepatic dysfunction); influenza A only• Unvaccinated high-risk patient (see [Table 11-7](#t0070){ref-type="table"})• Rimantadine (Flumadine) 100 mg bid PO × 5--7 days (reduce dose in elderly, in those with renal hepatic dysfunction); influenza A only• Oseltamivir (Tamiflu) 75 mg bid PO × 5 days (reduce dose in those with renal hepatic dysfunction); influenza A and B• Zanamivir (Relenza) two inhalations (10 mg) bid × 5 days; influenza A and B**Chemoprophylaxis Indications**• High-risk persons vaccinated after influenza activity has begun. Treat for 2 weeks after vaccine is given.• Amantadine (Symmetrel) 100 mg bid PO (reduce dose in elderly, in those with renal hepatic dysfunction); influenza A only• Unvaccinated persons, including healthcare workers, who provide care to high-risk persons during an outbreak. Treat for duration of outbreak or 2 weeks after vaccination.• Rimantadine (Flumadine) 100 mg bid PO (reduce dose in elderly, in those with renal hepatic dysfunction); influenza A only• Unvaccinated persons who have immunodeficiencies during an outbreak. Treat for duration of outbreak or 2 weeks after vaccination• Oseltamivir (Tamiflu) 75 mg qd PO (reduce dose in those with renal hepatic dysfunction); influenza A and B• Close unvaccinated contacts of persons with influenza. Treat for 7 days.• Residents of institutions (e.g., nursing homes) regardless of vaccination status. Treat for the duration of the outbreak.[^6]Adapted from: Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices, *MMWR* 54:1--40, 2005.

The neuraminidase inhibitors, oseltamivir (Tamiflu) and zanamivir (Relenza), were FDA approved in 1999 for treatment of adults with influenza A and B, and oseltamivir was approved for chemoprophylaxis in 2000. The most frequent adverse effects with oseltamivir include nausea and vomiting. Zanamivir is administered as an aerosol inhalant and, in addition to nausea and vomiting, some patients have experienced wheezing and a decline in pulmonary function.

Pharmacotherapy treatment for influenza should be initiated within 48 hours of the start of symptoms, and it been shown to reduce the duration of symptoms by only 1 day compared with placebo.[@bib0200] In addition to decreasing duration of symptoms, oseltamivir and zanamivir have been shown to decrease hospitalizations and the use of antibiotics.[@bib0200], [@bib0250] Chemoprophylaxis has been useful in preventing influenza in certain high-risk populations (see [Table 11-8](#t0080){ref-type="table"}).[@bib0200] Unfortunately, the use of antiviral agents as treatment and chemoprophylaxis has led to resistance, especially to amantadine and rimantadine.

Viral Hepatitis {#s0230}
===============

Hepatitis A {#s0240}
-----------

Hepatitis A is one of the most common vaccine-preventable diseases in the United States. It is caused by a picornavirus and produces both symptomatic and asymptomatic disease. Hepatitis A virus (HAV) infection is most often acquired through fecal-oral spread by either person-to-person transmission or from ingestion of a contaminated food or water source. Children often get asymptomatic disease and, thus, play an important role in transmission of the disease among family members and day care center staff.[@bib0260] The most frequently reported source of infection is a household member or sexual partner. Although 10% of those infected with hepatitis A have a history of one of the above exposures, up to 50% do not have an identifiable source. The case-fatality rate for hepatitis A in the United States is 0.3% but is higher among adults older than 50 years of age (1.8%) and in those with chronic liver disease. Groups at a higher risk for hepatitis A disease include international travelers, men who have sex with men (MSM), intravenous drug users, day care staff, and those who work with infected primates. Patients with clotting-factor disorders are also considered to be at a high risk through clotting factor transfusions. Healthcare workers and food handlers do not have a higher risk of disease but may be a source of transmission.

Hepatitis A has an average incubation period of 28 days (range, 15--50 days).[@bib0260] Symptoms including fever, malaise, nausea, abdominal pain, jaundice, scleral icterus, and dark urine last generally less than 2 months, but 10--15% of persons may have a prolonged or relapsing syndrome lasting up to 6 months. There is no chronic infection with hepatitis A; treatment is supportive because the infection is self-limited. The diagnosis of HAV infection is based on a combination of symptoms and the presence of serum transaminase (i.e., alanine aminotransferase and aspartate aminotransferase) and bilirubin elevations. Definitive diagnosis requires serologic evidence of acute disease via the presence of immunoglobulin M (IgM) anti-HAV. The presence of only IgG anti-HAV is not sufficient to diagnose acute hepatitis A, as approximately 33% of the US population has had exposure at some time.[@bib0260]

Prevention of HAV infection can be achieved through vaccination or passive immunization.[@bib0260] Inactivated whole-virus HAV vaccine is used in the United States and confers protection in 94--100% of adults. The two formulations used in the United States include Havrix and VAQTA. Adverse events from vaccination are rare and are usually limited to local irritation at the site of intramuscular injection. Twinrix, a combination vaccine containing HAV and hepatitis B components, should be administered in three doses at 0, 1, and 6 months. Complete seroprotection generally occurs 4 weeks after the first dose is received, and a second dose provides long-term protection (up to 7 years). International travelers, MSM, persons who use intravenous or intranasal illicit drugs, persons who have clotting-factor disorders, persons with occupational risk, and persons with chronic liver disease should be strongly encouraged to receive the HAV vaccine.

Immunoglobulin (IG) provides protection against HAV infection through passive transfer of antibodies from pooled human plasma.[@bib0240] IG is administered intramuscularly at a dose of 0.02 mL/kg and it provides up to 3 months of seroprotection. Hepatitis A IG should be administered prophylactically to unvaccinated exposed high-risk persons and should be administered simultaneously with HAV vaccine. Other eligible persons include those with close contact with a person with a confirmed case, staff at child care centers where an HAV infection outbreak has occurred, persons exposed to food prepared by an HAV-infected food handler, and travelers going to high-risk areas who have received HAV vaccine less than 2 weeks before traveling.

Hepatitis B {#s0250}
-----------

Hepatitis B virus (HBV) is a DNA virus that replicates primarily in the liver.[@bib0270] Like HAV, it is a vaccine-preventable disease; however, unlike HAV, a chronic disease state can occur with hepatitis B that can eventually lead to end-stage liver disease. HBV is primarily transmitted by percutaneous or mucosal exposure to infectious blood or body fluids that contain HBV. Persons at high risk of becoming infected with HBV include intravenous and intranasal drug users, persons engaging in unprotected sex with multiple partners, infants born to infected women, and healthcare workers. Recommendations to vaccinate infants and adolescents against HBV have resulted in a plummeting incidence of the disease in the United States---from 8.5/100,000 population in 1990 to 2.1/100,000 population in 2004. The prevalence of HBV infection in the United States is currently approximately 5%, and 1.5 million persons are chronic carriers of the virus. The incidence of infection in men is twice that in women (3.0/100,000 versus 1.5/100,000).[@bib0270]

The incubation period for HBV is 90 days (range, 60--150 days) from exposure to jaundice. Clinical symptoms of acute disease include anorexia, malaise, nausea, vomiting, and jaundice.[@bib0270] The fatality rate is up to 1.5% and is highest among persons older than 60 years of age. Asymptomatic disease also occurs and is more common in children younger than 5 years. Approximately 10% of acutely infected adults become chronic persistent carriers (i.e., hepatitis B surface antigen \[HBsAg\] positive), and 25--30% of these persons develop chronic active hepatitis.[@bib0270] Chronic HBV carriers are at an increased risk for hepatocellular carcinoma, cirrhosis, membranous glomerulonephritis, polyarteritis nodosum, and chronic serum sickness--like syndrome.

The diagnosis of acute HBV infection is based on clinical symptoms and serologic markers, particularly HBsAg.[@bib0270] Patients who eventually develop hepatitis B surface antibody (HBsAb) have cleared infection (or have been successfully vaccinated). If HBsAg does not clear by 4 months, then the patient is considered to be a chronic carrier. The presence of hepatitis B core IgG antibody (HBcAb) by itself is not adequate to confirm clearing of HBV, nor is it protective against the disease and its sequelae. Thus, persons who are HBcAb positive, HBsAb negative, and HBsAg negative should not be considered immune to HBV infection. Persons who are HBeAg positive are considered to be highly infective and are more likely to transmit the virus to others through unprotected sex or from an accidental needle stick. More recently, a PCR test has been used to quantify HBV DNA and to guide treatment for chronic disease. Immunocompromised patients (e.g., persons with HIV/AIDS) are less likely to clear virus from the blood.

No specific therapy exists for the treatment of acute HBV infection. However, several antiviral drugs including lamivudine (3TC), emtricitabine (Emtriva), adefovir (Hepsera), tenofovir (Viread), entecavir (Baraclude), and alpha-interferon (Cellferon) have been used in chronically infected patients to decrease HBV viral loads. Only entecavir, alpha-interferon, lamivudine, and adefovir have been approved by the FDA for treatment of HBV.

Prevention of HBV infection is best achieved through vaccination; however, hepatitis B immunoglobulin (HBIG) is also used in postexposure prophylaxis.[@bib0270] HBsAg is the antigen used for vaccination and is produced in the United States using recombinant DNA technology. The vaccine is available as a single-antigen formula (Recombivax HB, Engerix-B) or in combination with HAV vaccine (Twinrix). Since March of 2000, HBV vaccines do not contain thimerosal; all formulations are safe with minor site reactions being the most common adverse effect. Vaccination consists of three intramuscular injections at 0, 1, and 6 months for adults and children. In immunocompetent adults, vaccination is likely to be protective for 15--20 years. HBV vaccine is currently recommended in childhood and mandated by many states before children are allowed to enter school. Immunocompromised patients (e.g., persons with HIV/AIDS), patients receiving dialysis, persons receiving clotting factors via transfusion, healthcare workers and persons coming into contact with blood in the workplace, injection/intranasal drug users, persons with multiple sex partners, inmates and workers in correctional facilities, and international travelers should all strongly consider prophylactic vaccination.

Postexposure prophylaxis involves giving both HBIG and HBV vaccine.[@bib0280] HBIG is prepared from the plasma of donors with high concentrations of anti-HBs. Postexposure prophylaxis can be offered to persons who experience percutaneous or permucosal exposure to HBV. Unvaccinated persons should receive the hepatitis B vaccine and HBIG (0.06 mL/kg IM × 1 dose). If the person has been vaccinated and is a known responder, then no postexposure prophylaxis is required; if the person has been vaccinated but response status is unknown, then a serum antibody test should be performed. Patients with an adequate response (\>10 IU/mL) do not require postexposure prophylaxis, whereas those with an inadequate response should receive both HBIG and hepatitis B vaccine.

Hepatitis C {#s0260}
-----------

Hepatitis C virus (HCV) is a single-stranded RNA virus that causes chronic liver disease and is the most common reason for liver transplantation in the United States.[@bib0290] The prevalence of HCV antibody (anti-HCV) in the United States is 1.4%, and approximately 36,000 new infections occur every year. Thus, 3.9 million persons are anti-HCV positive, and between 8000 and 13,000 die each year from end-stage liver disease. The highest incidence of infection is among 20--39 year olds, and males and African Americans are more likely to develop chronic infection.[@bib0290]

HCV is transmitted through contact with infected blood or mucosal secretions.[@bib0300] Those at increased risk of acquiring HCV infection include intravenous and intranasal drug users, healthcare workers, persons having unprotected sex with multiple partners, and persons undergoing body piercing or tattoos; data on acquisition of the virus through sexual contact and tattooing have been inconsistent. Acquiring HCV infection through the blood supply or from blood products is unlikely today in the United States given current blood and blood product testing. Sexual transmission of HCV is reportedly lower than HBV, especially among monogamous couples, and transmission through casual contact is not believed to occur. Perinatal transmission occurs in 5% of infants born to anti-HCV--positive mothers.[@bib0300] Quite alarming is that 44% of newly diagnosed cases have no risk factors identified over the previous 6 months.[@bib0300]

Unlike HAV and HBV, acute infection with HCV is usually asymptomatic, and jaundice is present in fewer than 25% of cases.[@bib0310] Eighty percent of persons acutely infected with HCV remain anti-HCV positive, and 60--80% will have persistently elevated serum transaminase levels. Most patients with chronic HCV infection are asymptomatic and the only clue to disease is the elevated serum transaminase levels. Cirrhosis eventually develops in 7--17% of patients with chronic infection after an average of 20--25 years[@bib0310]; immunocompromised patients (e.g., persons with HIV/AIDS) and alcoholics may progress to cirrhosis more quickly. The development of cirrhosis is silent, but end-stage liver disease eventually occurs at a rate of 3.9% per year. These patients will eventually develop jaundice, ascites, anasarca, and esophageal varices and the mortality rate is 43% at 34 months unless liver transplant is performed.[@bib0310] Hepatocellular carcinoma develops at a rate of 3% per year in patients with cirrhosis.[@bib0310]

The diagnosis of HCV infection is difficult because few persons present symptomatically with acute disease[@bib0320]; many clinicians discover the infection on further investigation of incidental elevated serum transaminase levels. Given the success of newer treatments for HCV infection, an early diagnosis is essential. Currently, the American Association for the Study of Liver Diseases recommends that persons at high risk of infection (see above), recipients of transfusions or organ transplants before July 1992 (when HCV screening became standard), healthcare workers after a needlestick injury, and sexual partners of HCV-infected persons be tested.[@bib0320]

Persons who are found to be HCV positive should be counseled to avoid sharing dental and shaving equipment with others, to cover any bleeding wounds, and to avoid donating blood or blood products. In addition, HCV-infected persons should be counseled that the risk of sexual transmission is low and that infection is no reason to change sexual practices in a long-term relationship.[@bib0320] Diagnosis of HCV infection is achieved via serologic assays for anti-HCV. Those persons with a positive anti-HCV should undergo HCV PCR testing to quantify viral load and genotype testing to determine HCV type (e.g., type 1, 2). Selected patients should undergo a liver biopsy to determine the extent of hepatic disease.[@bib0320]

Treatment decisions should be individualized and are based on the severity of liver disease, the potential of serious adverse effects, the likelihood of treatment response, and the presence of comorbid conditions.[@bib0320] Thus, HCV-infected persons should be monitored by an expert in infectious diseases or hepatology. The current treatment of choice is pegylated interferon plus ribavirin for a period of 6--12 months.[@bib0320] Success of therapy depends on HCV genotype (genotype 1 is the most refractory to treatment), underlying comorbidities, and the extent of hepatic injury. A sustained viral response, defined as the absence of HCV virus in the blood 6 months after treatment, is achieved in 25--40% of treated persons. Re-treatment is sometimes necessary for nonresponders or in the case of relapse.[@bib0320]

Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome {#s0270}
===================================================================

Epidemiology/Pathogenesis {#s0280}
-------------------------

HIV is a human retrovirus that infects and destroys CD4-positive T cells (lymphocytes) that, over time, leads to severe immunodeficiency and allows for the development of opportunistic infections and neoplasms. HIV is transmitted from person to person through sexual intercourse, from mother to child via child birth or breast milk, or through infected blood products (including needlestick injuries). Since 1981, there have been approximately 25 million deaths attributable to HIV/AIDS worldwide.[@bib0330] Forty million people are estimated to be living with HIV infection globally in 2005, with 5 million people becoming newly infected and 3 million deaths yearly. In the United States, there are more than 1 million people currently living with HIV infection and more than 40,000 people with AIDS. In 2004, it was estimated that there were more than 15,000 AIDS-related deaths in the United States. In the early 1980s, MSM constituted the majority of new infections. More recently, in 2004, women accounted for 30% of new infections in the United States as heterosexual transmission rates have continued to rise.[@bib0340] Despite efforts at prevention focusing on condom use, HIV infection has remained a significant public health concern both globally and in the United States. In 2004, there were 15,737 deaths attributable to AIDS, 75% of which occurred in men.

Clinical Presentation {#s0290}
---------------------

Many people who are infected with HIV are unaware of their status since there often are no symptoms associated with chronic infection. Therefore, performing HIV antibody screening tests in patients who have high-risk exposures is of critical importance both for the health of the patient and to prevent HIV transmission to others. Conversely, up to 89% of patients who acutely are infected with HIV will have a constellation of symptoms consisting of fever, rash, myalgias, headache, and anorexia.[@bib0350] They also may develop laboratory abnormalities including thrombocytopenia and transaminitis. Unfortunately, these signs and symptoms are quite nonspecific and may be confused with other viral infections. Therefore, a high index of suspicion must be maintained and HIV testing must be performed if any risk factors are discovered after careful evaluation ([Table 11-9](#t0090){ref-type="table"} ). Identifying patients with acute HIV infection is important since people are most highly infectious to others at the time of initial infection, and since the virus is multiplying at a very high rate before an organized immune response. It remains unclear whether initiating antiretroviral therapy during this time is of clinical benefit, although this issue remains a subject of ongoing study since decreasing the rate of HIV replication early in the course of infection may theoretically preserve specific CD4 cell responses.[@bib0360] Table 11-9Risk Factors for Acquisition of HIV Infection[\*](#tn0020){ref-type="table-fn"}Unprotected sexual intercourse:• Men who have sex with men• Heterosexual intercoursePerinatal transmission from HIV-infected mother to child:• At time of child birth• Through breast milkExposure to contaminated blood or blood products:• Injection drug users who share contaminated needles• Healthcare worker needlestick injury• Healthcare worker blood product exposure to open wound or mucous membrane• Transfusion of contaminated blood or blood product[^7]

Diagnosis {#s0300}
---------

The standard method of screening for HIV infection is the HIV 1/2 enzyme-linked immunosorbent assay (ELISA). This test screens for antibodies that react against both HIV-1 and HIV-2 antigens. Although the test has very high sensitivity and specificity, false-positive results can occasionally occur when nonspecific cross-reacting antibodies are present. Therefore, confirmatory testing via the Western blot is essential for diagnosis because this test detects specific host antibody responses against certain HIV-1 epitopes. An HIV-1 Western blot analysis result is interpreted as positive when at least two of three bands are present: p24, gp41, and gp120/160. When a false-positive ELISA result is encountered, there is often only one of three bands present, or bands are present that do not correspond to known HIV-1 antigens.

The screening ELISA test result may be negative during the first 2 weeks after acute HIV infection, the "window period," since anti-HIV antibodies require time to develop. During an acute infection, as HIV is often replicating at very high levels, the diagnosis can be made by performing either a quantitative PCR assay for HIV RNA (viral load) or a qualitative proviral HIV DNA PCR assay. Confirmatory testing with a repeat ELISA at a later time remains mandatory.[@bib0370]

Treatment {#s0310}
---------

An enormous amount of research effort has been directed toward developing effective therapeutic strategies for HIV infection over the past 20 years. Since 1996, when multiple antiretroviral medications became available that acted at different stages of the viral life cycle, the long-term prognosis for patients living with HIV infection has improved dramatically. Pharmacotherapy is now available in four different classes that act to disrupt viral replication at the level of HIV RNA to DNA transcription (nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors), HIV capsid assembly (protease inhibitors), and HIV fusion to the CD4 positive T cell (fusion inhibitors). These drugs are used in certain combinations under the guidance of an HIV specialist to create highly active antiretroviral therapy that fully suppresses HIV replication and allows the regeneration of CD4 cells that reconstitute the patient\'s immune system to improved levels of functioning.[@bib0380]

When the immune system is successfully reconstituted, patients are no longer at a high risk for the opportunistic infections associated with the morbidity and mortality that occurs with AIDS. Currently, not all patients with HIV infection require the use of antiretroviral medication. Because of the adverse effects and the risk of the development of resistance associated with treatment, these medications are now initiated only when the CD4 count falls to below 350 cells/mL or in the setting of acute infection.[@bib0380]

Complications {#s0320}
-------------

The morbidity and mortality associated with HIV infection are due to the consequences of immune suppression (i.e., AIDS) and to the sometimes serious adverse effects of antiretroviral medications. If viral replication is left unmonitored in patients who are not diagnosed early in the course of HIV infection or in patients who develop resistance to antiretroviral medications, then the CD4 count inexorably declines over time in most cases. The end result is a loss of appropriate functioning of the immune system, which allows for the development of both opportunistic infections and neoplasms ([Table 11-10](#t0100){ref-type="table"} ).Table 11-10Selected AIDS-associated Opportunistic Infections and NeoplasmsCentral nervous system toxoplasmosisCervical cancerCryptococcosis (including meningitis)Cytomegalovirus (CMV) retinitisEsophageal candidiasisHIV encephalopathyHistoplasmosis (including disseminated disease)Kaposi sarcomaLymphoma*Mycobacterium avium* complex (including disseminated infection)*Mycobacterium tuberculosis*Oral thrush*Pneumocystis jerovici* pneumoniaProgressive multifocal leukoencephalopathyRecurrent bacterial pneumoniaAdapted from: Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, *MMWR Morb Mortal Wkly Rep* 41(No. RR-17):1--18, 1992.

Different opportunistic infections may be observed at various levels of immune suppression depending on the CD4 count level. With relatively normal CD4 counts (500 cells/mL or greater), patients with HIV infection encounter a greater risk of bacterial infections, including pneumonia and soft tissue infections.[@bib0390] Reactivation of herpes virus infections such as herpes simplex virus (HSV) and varicella zoster may also occur in this range. Patients become at a high risk for Kaposi sarcoma and tuberculosis when CD4 counts fall between 200 and 400 cells/mL. More severe immune compromise occurs at CD4 count levels of less than 200 cells/mL, at which point prophylactic antibiotics such as TMP/SMX are recommended.[@bib0390] Patients in this range are at risk for *Pneumocystis jerovici* (formerly *Pneumocystis carinii*) pneumonia, cryptococcosis, and toxoplasmosis reactivation. Patients are considered to be profoundly immune compromised when the CD4 count drops below 50 cells/mL, at which point they are at risk for other severe infections including disseminated *Mycobacterium avium* complex, cytomegalovirus reactivation, and lymphoma.[@bib0400]

Over the past 10 years, HIV specialists have learned that although antiretroviral medication can dramatically alter the natural history of HIV and AIDS, they also carry the risk for adverse effects and drug interactions.[@bib0380] Each individual medication and class of medication has a unique set of potential adverse effects, some of which are irreversible. For example, protease inhibitors and some nucleoside reverse transcriptase inhibitors have been linked to the development of fat redistribution syndromes (peripheral lipodystrophy). Glucose intolerance and hyperlipidemia can occur with the use of some protease inhibitors as well including lopinavir/ritonavir (Kaletra).[@bib0380] Mitochondrial toxicity leading to lactic acidosis can be caused by any of the nucleoside reverse transcriptase inhibitors and has been particularly linked to the use of stavudine (Zerit) and didanosine (Videx), especially when used together.[@bib0380] The non-nucleoside reverse transcriptase inhibitors such as nevirapine (Viramune) can cause a drug-induced hepatitis and sometimes severe cutaneous drug eruptions.[@bib0380] Although antiretroviral therapy has significantly reduced the morbidity and mortality associated with HIV infection and has been of great benefit to many patients, these drugs must be used judiciously to minimize the risk of severe toxicity.

Prevention {#s0330}
----------

Until an effective vaccine is developed, the key to eliminating the threat of the spread of HIV is through prevention efforts.[@bib0410], [@bib0420] Educating patients about the importance of condom use to prevent the spread of sexually transmitted diseases such as HIV is of paramount importance. Intravenous drug users can minimize their risk through needle-exchange programs. In the case of occupational exposures (e.g., needlestick injuries) or sexual assault, postexposure prophylaxis with antiretroviral drugs can significantly reduce the risk of infection.[@bib0430], [@bib0440] Lastly, it is important that physicians work closely with their local health departments so that sexual partners of HIV-infected patients can be notified and tested and the chain of ongoing risk of HIV transmission to others can be broken.

Infectious Diarrheas {#s0340}
====================

Epidemiology/Microbiology {#s0350}
-------------------------

In the United States, nearly 400 million episodes of diarrheal illness occur each year or, on average, one diarrheal episode per person per year.[@bib0450] Food-borne diarrhea accounts for one fifth of these cases (80 million) and is the cause of 5000 deaths per year. Although the highest mortality worldwide occurs among children, in the United States most of those who die from diarrheal disease are elderly.[@bib0450]

Since many different microorganisms can cause infectious diarrhea, it is useful to divide them into three groups: community-acquired or traveler\'s diarrhea, nosocomial diarrhea, and persistent diarrhea (diarrhea lasting for greater than 7 days) ([Table 11-11](#t0110){ref-type="table"} ).[@bib0450] The most common community-acquired organisms include viruses such as Norovirus, Enterovirus, and Rotavirus and bacteria including *Campylobacter, Salmonella* species *(*non-*typhi), Shigella* species, *Escherichia coli,* and enterotoxigenic *S. aureus.* A new vaccination is available for rotavirus and is administered to children at 2, 4, and 6 months of age; the previous version of the vaccination was taken off the market several years ago as a result of numerous fatal cases of intussusception. Traveler\'s diarrhea is most likely to be caused by *E. coli,* but *Entamoeba histolytica* and *Salmonella typhi* must also be included. Nosocomial diarrhea is almost exclusively caused by *Clostridium difficile,* although *S. aureus* has been implicated in some cases. Both of these diarrheas are associated with antibiotic use. Although clindamycin is classically associated with *C. difficile* infection, any antibiotic (particularly broad-spectrum antibiotics) can cause the disease. Persistent diarrheas are most commonly caused by protozoal organisms including *Giardia lamblia, Cryptosporidium, Cyclospora,* and *Isospora belli.* Table 11-11Common Causes of Infectious DiarrheaOrganismMode of TransmissionTreatment**Viruses**RotavirusTransmitted person to person; transmitted through contaminated food or liquidViral gastroenteritis is self-limited and does not require antibiotic treatmentNorovirusEnteroviruses**Bacteria***Shigella* speciesPerson to person; food (rare)TMP-SMZ (160/800 mg); fluoroquinolone (e.g., ciprofloxacin 500 bid PO); ceftriaxone IM/IV; azithromycin 500 mg qd PO × 3 days. Use IV if patient not taking PONon-*typhi Salmonella*Food associated (e.g., chicken, eggs)Generally no treatment Treat severe disease, younger than 6 months or older than 50 years, compromised (see Shigella) × 5--7 days*Campylobacter* speciesFood (e.g., chicken), milkErythromycin 500 mg bid × 5 days*Escherichia coli* speciesFood (e.g., beef, fresh produce), water, raw milkTMP-SMZ (160/800 mg); fluoroquinolone (e.g., ciprofloxacin 500 bid PO); ceftriaxone IM/IV; azithromycin 500 mg qd PO × 3 daysEnterotoxigenicEnteropathogenicEnteroinvasive*Escherichia coli* 0157 enterohemorrhagicFood (e.g., beef), waterAvoid antimotility drugs; Avoid antibiotics*Aeromonas, Plesiomonas*WaterTMP-SMZ (160/800 mg); fluoroquinolone (e.g., ciprofloxacin 500 bid PO); ceftriaxone IM/IV; azithromycin 500 mg qd PO × 3 days*Yersinia* species (not pestis)Food (e.g., pork), milkNo treatment*Staphylococcus aureus*Food (e.g., egg salad, ham, poultry, pastries)No treatment*Bacillus cereus*Food (e.g., fried rice, meats)No treatment*Clostridium perfringens*Food (e.g., beef, poultry, gravy)No treatment*Clostridium difficile*Antibiotic associatedStop antibiotic; metronidazole 250 mg PO qid to 500 mg tid × 10 days**Parasites***Giardia*WaterMetronidazole 250--750 mg PO tid × 10 days*Entamoeba histolytica*Water, food (fresh produce)Metronidazole 750 mg PO tid × 5--10 days + paromomycin 500 mg tid × 7 days*Cryptosporidium*WaterUsually self-limited[^8]Adapted from: Guerrant RL, Van Gilder T, Steiner TS, et al: Practice guidelines for the management of infectious diarrhea, *Clin Infect Dis* 32:331--351, 2001.

Populations at increased risk of developing infectious diarrheas include young children, immunocompromised patients, and patients taking antibiotics. HIV-positive patients are at a particular risk of acquiring protozoal diarrheal infections such as *Entamoeba histolytica* and *Cryptosporidium*. The low gastric pH in children younger than 5 years places them at a significantly increased risk for *Salmonella* infections.

Clinical Evaluation {#s0360}
-------------------

A thorough history should be the first step in determining the source of an infectious diarrhea. In patients who have recently traveled overseas (within 2 weeks) *E. coli, Entamoeba,* and *S. typhi* should be considered.[@bib0460] Endemic food-associated diarrheas are caused by organisms including *Campylobacter, S. aureus, Salmonella typhimurium, Shigella, Listeria,* and noroviruses (see [Table 11-11](#t0110){ref-type="table"}). Seasonal diarrhea might implicate enteroviruses or Rotavirus. Diarrhea occurring after consumption of untreated water is suggestive of *Giardia* or *E. coli* infection. A complete exposure history is particularly critical in food-associated diarrheas that have public health implications; all documented infections should be reported to respective counties for epidemiologic surveillance.

The timing and character of the diarrhea often helps in establishing an etiology.[@bib0460] Rapid onset (within 2--6 hours) is characteristic of toxin-mediated diarrheas such as *S. aureus* and *Bacillus cereus.* A somewhat longer period from exposure to onset of symptoms (8--16 hours) is commonly seen in *Clostridium perfringens* toxin-mediated diarrhea. *Salmonella, Shigella,* and *Campylobacter* generally have incubation periods of 16--48 hours. Chronic diarrheas lasting 1--3 weeks are typical of *Cryptosporidium* and *Giardia* infections. Bloody diarrhea with fever and tenesmus is referred to as *dysentery* and indicates an invasive process. Although this presentation is characteristic of *Entamoeba* and *Shigella*, it is sometimes seen with *Campylobacter* and *Salmonella.* A profuse secretory diarrhea (i.e., "rice water diarrhea") that can lead to rapidly fatal dehydration is caused by *Vibrio cholera*. Diarrhea associated with upper gastrointestinal signs such as bloating and belching is typical of *G. lamblia.* Diarrhea with fevers and a high white blood cell count in a hospitalized patient should raise concern for *C. difficile* infection. Bloody diarrhea without fever that is associated with renal failure (hemolytic uremic syndrome) suggests enterohemorrhagic *E. coli* (EHEC 0157) infection.

Laboratory Diagnosis {#s0370}
--------------------

Selective fecal testing is useful in the following situations: (1) community-acquired or traveler\'s diarrhea, especially if accompanied by fever and bloody stools; (2) nosocomial diarrhea occurring 3 days after hospitalization; and (3) persistent diarrhea lasting longer than 1 week.[@bib0450] Fecal leukocyte testing may help to identify an inflammatory diarrhea but is a neither specific nor sensitive. Stool culture and assessment for ova and parasites should be used for investigation of community-acquired and traveler\'s diarrheas. Because most infectious diarrheas are self-limited, these tests should be used for epidemiologic studies and for those patients who present with bloody diarrhea and fever. In patients hospitalized for more than 3 days, stool cultures for community-acquired organisms (e.g., *Campylobacter, S. aureus, S. typhimurium, Shigella, Listeria*) and ova and parasites are unlikely to be helpful and should not be performed.[@bib0450] These patients should, however, be tested for *C. difficile* toxin.[@bib0450] In patients with continued diarrhea with no identified pathogen, a colonoscopy may be helpful in identifying noninfectious causes of diarrhea, such as inflammatory bowel disease.

Management and Treatment {#s0380}
------------------------

Treatment of dehydration is the cornerstone of therapy of community-acquired infectious diarrheas because most of these infections are self-limited.[@bib0450] Oral hydration with an electrolyte solution (e.g., Pedialyte, World Health Organization rehydration solution) is preferred, but if the patient cannot sustain oral rehydration, then parenteral hydration may be necessary. Although traveler\'s diarrhea is usually self-limited, TMP-SMZ or a fluoroquinolone can reduce the duration of illness from 3--5 days to 1--2 days.[@bib0450] Patients with fever and bloody diarrhea should be treated empirically with TMP-SMZ or a fluoroquinolone.[@bib0450] These patients are most likely to have invasive disease with *Shigella* or *Campylobacter* species. Antimotility agents can be used for uncomplicated traveler\'s diarrhea but should be avoided in patients with fever and bloody diarrhea or those with fecal leukocytes.[@bib0450] Treatment of EHEC 0157 with antimicrobial agents has been associated with an increased risk of hemolytic uremic syndrome and should therefore be considered carefully. [Table 11-11](#t0110){ref-type="table"} details various treatment regimens for infectious diarrhea commensurate with each pathogen.

Complications {#s0390}
-------------

The most devastating complication of an infectious diarrhea is toxic megacolon and bowel perforation.[@bib0470] This should be suspected in patients who have a sudden increase in pain, decreased bowel sounds, and a septic appearance. Rebound pain or guarding on palpation of the abdomen are characteristic findings and should prompt immediate surgical evaluation. Invasive organisms are most likely to cause this complication and include *Entamoeba, Shigella, C. difficile, C. perfringens,* and enteropathogenic *E. coli* infection. Enterohemorrhagic *E. coli* infection is associated with hemolytic uremic syndrome in children but rarely occurs in adults. *Entamoeba* infection can lead to amoebic liver abscesses, which require additional antibiotic treatment and sometimes drainage. Dehydration is the leading cause of death in developing countries from infectious diarrheas, particularly via *V. cholera*. Bacteremia can occur with *S. typhimurium* in immunocompromised patients (e.g., persons with HIV/AIDS).

Sexually Transmitted Diseases {#s0400}
=============================

Urethritis {#s0410}
----------

*Urethritis* is defined as the presence of urethral inflammation. It is clinically characterized by the discharge of mucopurulent or purulent material and by dysuria or urethral pruritus. The classic bacterial pathogen of acute urethritis is *Neisseria gonorrhoeae*. Urethral infection of all other causes is referred to collectively as nongonococcal urethritis (NGU). The organism most clearly associated with NGU is *Chlamydia trachomatis* (15--55% of cases).[@bib0480] The pathogens responsible for *Chlamydia*-negative NGU include *Ureaplasma urealyticum, Trichomonas vaginalis, Mycoplasma genitalium,* and HSV. The etiology of most cases of non-chlamydial NGU is unknown.

Urethritis can be documented on the basis of any of the following signs: mucopurulent or purulent discharge, a Gram stain of urethral secretions demonstrating 5 or more white blood cells per high power field, microscopic examination demonstrating 10 or more white blood cells per high power field, or a positive leukocyte esterase test on first-void urine.[@bib0480] The Gram stain is a highly sensitive and specific test for evaluating urethritis and the presence or absence of gonococcal infection. Gonococcal infection is established by documenting the presence of white blood cells containing intracellular gram-negative diplococci.

### Gonococcal Urethritis {#s0420}

The rate of gonorrhea infection in males in the United States is most common in African American men aged 20--24 years.[@bib0490] Historically, the reported rates of gonococcal infection in men is higher than in women, differences attributable to the higher incidence of asymptomatic disease in women and the occurrence of infection among MSM, as the incidence of gonococcal infection has been increasing in the latter population.[@bib0490] Gonorrhea in MSM is associated with an approximately three-fold increase in the risk of acquisition of HIV infection.[@bib0500]

Acute urethritis is the predominant manifestation of gonorrhea in men. The incubation period is typically 2--5 days, but recent studies suggest that this may be increasing.[@bib0510] Dysuria is usually more prominent and the discharge is generally more profuse and purulent than NGU. Epididymitis, proctitis, and pharyngitis are less common complication of *N. gonorrhoeae* infection. Anorectal gonorrhea is frequently the only site of infection in MSM and is uncommon in heterosexual men. Symptoms of proctitis include a mucopurulent rectal discharge, anal pruritus, tenesmus, pain, and rectal bleeding. Oropharyngeal infections with *N. gonorrhoeae* are frequently asymptomatic. First-line treatment for gonococcal pharyngeal infection is either intramuscular ceftriaxone or oral ciprofloxacin.[@bib0480]

Disseminated gonococcal infection results from gonococcal bacteremia and is often highlighted with petechial or pustular acral skin lesions, asymmetrical arthralgia, tenosynovitis, or septic arthritis.[@bib0480] It is a relatively common cause of infective arthritis in young adults. Gonococcal bacteremia often is intermittent, so that a minimum of three blood cultures should be obtained when disseminated disease is suspected. Approximately one half of patients with a disseminated gonococcal infection will have positive cultures of blood or synovial fluid.[@bib0520] Hospitalization is recommended for initial therapy, especially for patients who may not comply with treatment. Patients should be examined for clinical evidence of endocarditis and meningitis. The recommended regimen for disseminated gonococcal infection is intramuscular or intravenous ceftriaxone (1 g every 24 hours).[@bib0480]

Culture for *N. gonorrhoeae* remains the gold standard for diagnosis. Urethral, rectal, and pharyngeal specimens can be obtained using cotton swabs plated on Thayer-Martin agar. Nucleic acid amplification tests offer noninvasive, rapid results on both urine and urethral specimens and are the most commonly used assays in practice today. The sensitivity and specificity of nucleic acid amplification tests via both specimens is similar, and in some studies greater, than via standard culture.[@bib0480] Recommended treatment regimens for gonococcal urethritis and proctitis include ceftriaxone, cefixime, ciprofloxacin, ofloxacin, or levofloxacin in single doses ([Table 11-12](#t0120){ref-type="table"} ). Quinolone-resistant *N. gonorrhoeae* is common in Hawaii, California, and parts of Asia and the Pacific and among MSM,[@bib0440] and thus quinolones are no longer recommended for the treatment of gonorrhea in these areas or in MSM; the first-line therapy for these groups is ceftriaxone.[@bib0480]A detailed travel history for the patient and his or her partners is recommended before a therapy is chosen. If chlamydial infection is not ruled out and suspicion is high, then azithromycin or doxycycline should be given concomitantly.[@bib0480] Table 11-12Treatment of Sexually Transmitted DiseasesOrganismPrimary TherapyAlternative Therapy*Treponema pallidum* (syphilis)Primary, secondary, and early latent: benzathine PCN G 2.4 million units IM Late latent or latent of unknown duration, tertiary (excluding neurosyphilis): benzathine PCN G 7.2 million units IM, 2.4 million units/week × 3 weeks IM Neurosyphilis: Aqueous crystalline PCN G 18--24 million units/day (3--4 million units every 4 hours IV) for 10--14 daysPCN allergy: Doxycycline 100 mg bid × 14 days or tetracycline 500 mg qid × 14 days or azithromycin 2 g PO single dose ± PCN allergy: Doxycycline 100 mg bid × 28 days or tetracycline 500 mg qid × 28 days Procaine PCN G 2.4 million units IM qd + probenecid 500 mg PO qid, both for 10--14 days*Neisseria gonorrhoeae* (gonococcal urethritis)Single doses: Ceftriaxone 125 mg IM or cefixime 400 mg PO or ciprofloxacin 500 mg PO or ofloxacin 400 mg PO or levofloxacin 250 mg POSingle doses: Cefotaxime 500 mg IM or cefoxitin 2 g IM with probenecid 1 g PO or spectinomycin 2 g IM*Chlamydia trachomatis* (non-gonococcal urethritis)Azithromycin 1 g PO single dose or doxycycline 100 mg PO bid for 7 daysErythromycin 500 mg PO for 7 days or ofloxacin 300 mg bid for 7 days or levofloxacin 500 mg PO for 7 days*Chlamydia trachomatis* (lymphogranuloma venereum)Doxycycline 100 mg PO bid × 21 daysErythromycin 500 mg PO qid × 21 days*Haemophilus ducreyi* (chancroid)• Azithromycin 1 g PO × 1• Ciprofloxacin 500 mg PO bid × 3 days• Ceftriaxone 250 mg IM × 1• Erythromycin 500 mg PO qid × 7 daysHuman papilloma virus (HPV)• Podophyllin solution topically qod × 3--4 weeks• Imiquimod (Aldara) cream 3×/week for 10--16 weeks• Benzoin tincture every week × 4 weeks• Trichloroacetic acid every week × 4 weeks• 5-flourouracil cream qd × 5--7 days• Intralesional alpha-interferon qod × 8--12 weeks• Removal-cryosurgery, electrosurgery, laser surgery, surgical excisionHerpes simplex virus (HSV) (genital ulcers)**TreatmentTreatment**• Acyclovir 400 mg PO tid × 7--10 days• Acyclovir 200 mg PO 5×/day × 7--10 days• Famciclovir 250 mg PO tid × 7--10 days• Valacyclovir 1 g PO bid × 7--10 days**SuppressionSuppression**• Acyclovir 400 mg PO bid• Acyclovir 200 mg PO 2--5×/day• Famciclovir 250 mg PO bid• Valacyclovir 500 mg PO qd[^9]Adapted from: Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002, *MMWR Recomm Rep* 51(No. RR-6):1--78, 2002.

### Nongonococcal Urethritis {#s0430}

The prevalence of *C. trachomatis* differs by age group, with a lower prevalence seen among older men; the number of cases due to this pathogen appears to be decreasing.[@bib0530] Most cases of NGU are sexually acquired. The incubation period of NGU is variable, but is typically 5--10 days after exposure. Patients with NGU have a less acute onset than gonorrhea, with symptoms increasing over several days. Patients typically present with a mucoid or watery discharge. Many men who are infected with *C. trachomatis* or *N. gonorrhoeae* are asymptomatic. The diagnosis of chlamydial urethritis is best made by nucleic acid amplification tests using PCR. Treatment for NGU is azithromycin or doxycycline (see [Table 11-12](#t0120){ref-type="table"}).[@bib0480]

*C. trachomatis* can also cause proctitis, epididymitis, prostatitis, and reactive arthritis or Reiter syndrome. Asymptomatic chlamydial infection has not been associated with infertility in men. Chlamydial proctitis, defined as inflammation of the distal rectal mucosa, is relatively uncommon and occurs almost exclusively in MSM. Acute epididymitis is most commonly caused by *N. gonorrhoeae* or *C. trachomatis* among sexually active men younger than 35 years old. Symptoms include unilateral testicular pain and tenderness, hydrocele, and palpable swelling of the epididymis. Treatment for acute epididymitis caused by *N. gonorrhoeae* or *C. trachomatis* is ceftriaxone (250 mg intramuscular as a single dose) plus doxycycline (100 mg orally twice daily for 10 days).[@bib0480]

### Follow-up for Gonococcal Urethritis and Nongonococcal Urethritis {#s0440}

Patients should be instructed to return for evaluation if symptoms persist or recur after completion of therapy. Patients should be instructed to abstain from sexual intercourse until 7 days after therapy is initiated. Patients should refer for evaluation and treatment all sex partners they have had within the preceding 60 days. Sexual partners are often asymptomatic and, unless treated, will reinfect the index patient or spread infection to other partners. Patients who have persistent or recurrent urethritis should be re-treated with the initial regimen if they did not comply with the treatment regimen or if they were re-exposed to an untreated sex partner.[@bib0480] Persistent gonococci that are isolated should be tested for antibiotic susceptibility. Persistent urethritis may also be caused by other organisms including *U. urealyticum* and *T. vaginalis.*

Syphilis {#s0450}
--------

Syphilis is a spirochetal disease caused by *Treponema pallidum* and is most often acquired sexually. The incidence of primary and secondary syphilis increased between 2001 and 2004, with the increases observed only among men.[@bib0490] The rate of primary and secondary syphilis among males rose 81% between 2000 and 2004.[@bib0490] The natural history of syphilis is divided into several stages that sometimes overlap:•Primary syphilis: After an incubation period of 10--90 days (usually 3 weeks), a painless papule appears at the site of inoculation, usually the external genitalia, anal area, lips, oral cavity, breasts, or fingers. This lesion ulcerates within a few days, producing the classic painless chancre, which usually resolves in 3--6 weeks.•Secondary syphilis: Weeks to months later, the majority of untreated patients will develop symptoms and signs of secondary syphilis including diffuse lymphadenopathy, focal alopecia, mucosal lesions, and condyloma lata. A classic rash, characterized as a symmetric red and papular eruption involving the entire trunk and extremities including the palms and soles where it can become squamous, is the most characteristic finding of secondary syphilis, occurring in approximately 90% of patients. Nonspecific symptoms include fever, headache, malaise, anorexia, sore throat, myalgias, and weight loss.•Latent syphilis: If untreated, clinical manifestations of secondary syphilis last for 2--6 weeks. Latent syphilis starts after the resolution of secondary syphilis and is defined by a positive serologic test result in an asymptomatic patient. Infection of less than 1 year is defined as early latent (infectious) and of more than 1 year as late latent (noninfectious).[@bib0480]•Tertiary syphilis: After a variable level of latency, tertiary syphilis develops in about one third of untreated patients presenting as gummatous (i.e., nodules found anywhere in the body, most often in the skin and bones), cardiovascular, or neurosyphilis manifestations.[@bib0540]

Neurologic involvement can occur during all stages of syphilis. Acute asymptomatic or symptomatic meningitis can be seen during primary or secondary syphilis. The most fearful manifestations of CNS involvement occur during tertiary syphilis including meningovascular syphilis (leading to cerebrovascular accidents) and parenchymatous syphilis (general paresis or tabes dorsalis).

The diagnosis of syphilis is made by microscopy or serologic tests. Darkfield examinations and direct fluorescent antibody tests of lesion exudates or tissue are the definitive methods for diagnosing early syphilis.[@bib0480] Serologic tests for syphilis are classified into nontreponemal and treponemal assays. Nontreponemal tests include the Venereal Disease Research Laboratory (VDRL) and Rapid Plasma Reagin tests. Treponemal tests include the fluorescent treponemal antibody absorbed and *T. pallidum* particle agglutination tests. The use of only one type of serologic test is insufficient for diagnosis because false-positive nontreponemal test results may occur as a result of various medical conditions (e.g., autoimmune diseases). The nontreponemal tests are recommended as screening tools, and the treponemal tests are required for confirmation. Nontreponemal tests usually correlate with disease activity and usually become nonreactive with time, which can provide a false-negative result if they are the sole test performed in a patient with a previous infection. Reactive treponemal tests usually remain reactive regardless of treatment or disease activity. Some HIV-infected patients can have atypical serologic tests results (unusually high, unusually low, or fluctuating titers).[@bib0480] Positive cerebrospinal fluid (CSF) VDRL results are diagnostic of neurosyphilis, if the specimen is not contaminated with blood. CSF leukocytosis and increased CSF protein levels are common in cases of neurosyphilis.

Parenteral administration of penicillin G is the preferred drug for treatment for all stages of syphilis.[@bib0480] The preparations used (e.g., benzathine, aqueous procaine, or aqueous crystalline), the dosage, and the length of treatment depend on the stage and clinical manifestations of disease (see [Table 11-12](#t0120){ref-type="table"}).

Chancroid {#s0460}
---------

Chancroid is a sexually transmitted disease caused by the bacteria *Haemophilus ducreyi.* It is rare in the United States, with a steady decline in cases from a high of 5000 in 1987 to 39 cases in 2004. Men are more commonly infected than women, and 60% of all cases occur in persons aged 35 years or older.[@bib0550] *H. ducreyi* is highly infectious, and having only 100 colony-forming units leads to disease in 90% of exposed persons. Because it is difficult to grow, disease may be underestimated. Chancroid presents as a painful genital papule after 4--10 days of incubation. The papule becomes a 1--2-cm ulcer with an erythematous base and a clear, undermined border. The lesions most commonly occur on the prepuce, corona, or glans of the penis, and one half of infected men will progress to develop painful inguinal lymphadenitis.

The diagnosis of chancroid is challenging and depends on clinical presentation, a negative result in a test for HSV, and a Gram stain revealing small gram-negative rods in chains.[@bib0560] Culture of *H. ducreyi* is difficult and beyond the capability of most labs in the United States. Treatment is successful in 90% of cases, and the drugs of choice include azithromycin or ceftriaxone (see [Table 11-12](#t0120){ref-type="table"}). Fluctuant inguinal buboes (severe lymphadenitis) should be drained by needle aspiration or they may develop draining fistulas. Sex partners should be treated, regardless of signs or symptoms, if they have had sexual contact with the infected person within 10 days of symptom presentation.

Lymphogranuloma Venereum {#s0470}
------------------------

*C. trachomatis* infection can also lead to lymphogranuloma venereum.[@bib0480] This disease is most common in tropical and subtropical areas, represents less than 1% of all genital ulcers in the United States, and is more common among MSM. Clinically, it is characterized by a painless genital ulcer that initially heals but is followed in 2--6 weeks by painless inguinal lymphadenopathy. Untreated lymphogranuloma venereum progresses to inguinal buboes with chronic fistulous tracts. Diagnosis is often challenging and is based on a high degree of clinical suspicion and a positive IgG test for chlamydia (\> 1:256). Antibiotic treatment for lymphogranuloma venereum is outlined in [Table 11-12](#t0120){ref-type="table"}.

Human Papilloma Virus {#s0480}
---------------------

Human papilloma virus (HPV) is a DNA virus that causes penile and perirectal warts in men.[@bib0480] The prevalence of anal HPV (i.e., PCR positive) in MSM is approximately 57% and the most common genotype seen is HPV-16, a high-risk type associated with anal cancer. Nineteen percent of men attending sexually transmitted disease clinics in the United States have been found to be seropositive for HPV-16.[@bib0480] The most consistent risk factor for HPV acquisition is unprotected sexual activity and is directly related to the number of sexual partners a patient has had. In men, HPV most commonly presents as a painless, cauliflower-like anogenital wart (i.e., condyloma acuminatum) that grows over time. Although the diagnosis of HPV is most often made on a clinical basis, definitive diagnosis can be obtained via biopsy. There is currently no antiviral medication available for HPV eradication; however, ablative treatment is useful (see [Table 11-12](#t0120){ref-type="table"}). HPV can be transmitted even when lesions are not present, and condom use does not guarantee protection because the virus is often transmitted through nonpenetrative sexual contact. Males who practice anal receptive intercourse should have yearly examinations for anal warts and, if lesions are present, a biopsy should be performed to evaluate for anal cancer. A vaccine against many serotypes of HPV (Gardasil) has shown success in various trials and was approved by the FDA in 2006, but it currently only has an indication in females aged 9--26 years.

Herpes Simplex Virus Types 1 and 2 {#s0490}
----------------------------------

Herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) were linked to more than 200,000 genital infections in 2003, and it is estimated that more than 30 million persons in the United States currently have genital HSV. Although HSV-2 is responsible for most cases of genital infection, the prevalence of HSV-1 is rising, especially among women. The highest rates of HSV-2 seroprevalence in the United States have been reported among female prostitutes and homosexual males (83%).[@bib0570] Males are only one half as likely as females to be infected with both HSV-1 and HSV-2.[@bib0570] There is a wide spectrum of HSV genital disease, ranging from asymptomatic shedding to a painful genital ulcer with dysuria, painful inguinal adenopathy, and fever. In men, a vesicular penile ulcer with an erythematous base and dysuria are the most common presenting symptoms. Recurrent genital lesions are common, especially with HSV-2 (60%).[@bib0570] Nineteen days is the average duration of lesions seen in primary infection, and this decreases by up to 10 days with recurrences. Although transmission to sexual partners is higher with active lesions, 70% of transmissions are attributed to asymptomatic viral shedding. Transmission is greater with male versus female source patients (17% versus 4%). Diagnosis is usually suggested by a painful, shallow, genital ulcer, but viral culture, direct fluorescent antibody testing, and PCR can be used as confirmatory tests.[@bib0570] PCR is especially useful in the diagnosis of asymptomatic carriage. Serologies are most helpful for epidemiologic studies and are not useful acutely to diagnose infection. Various treatment options for HSV genital infection are outlined in [Table 11-12](#t0120){ref-type="table"}.[@bib0480]

Conclusion {#s0500}
==========

We have provided an evidence-based summary of several of the most important infections in men. A more exhaustive rendition of each infection can be found in the associated references. Education regarding minimizing communicable transmission of infectious diseases as well as early testing and treatment remain the standard in the movement toward minimizing morbidity and mortality.

[^1]: bid, Twice a day; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IV, intravenous; PO, per os; MIC, mean inhibitory concentration.

[^2]: DS, Double strength; qid, four times a day; IV, intravenous; IM, intramuscular.

[^3]: Considered to be first-line therapy.

[^4]: IV, Intravenous; PO, per os; OM, otitis media; OE, otitis externa.

[^5]: ACIP, Advisory Committee on Immunization Practices; GBS, group B *Streptococcus.*

[^6]: bid, Twice a day; PO, per os; qd; once a day.

[^7]: HIV cannot be transmitted through casual contact.

[^8]: TMP-SMZ, trimethoprim/sulfamethoxazole; bid, twice a day; PO, per os; IM, intramuscular; IV, intravenous; qid, four times a day; tid, three times a day; qd, once a day.

[^9]: IM, Intramuscular; bid, twice a day; qid, four times a day; PO, per os; qd, once a day; qod, every other day.
